Drug Trial Radar · NCT02979522
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
59
Actual
Start
Sep 6, 2017
Primary completion
May 5, 2020
Study completion Sep 24, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).
Conditions
- Hodgkin Disease
Interventions
Brentuximab vedotinDrug
Brentuximab vedotin infusion
DoxorubicinDrug
Doxorubicin infusion
VinblastineDrug
Vinblastine infusion
DacarbazineDrug
Dacarbazine infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine in a Pediatric PopulationTime frame: From the first dose (Cycle 1) up to Day 56 (Cycle length=28 days)
- Phase 1: Percentage of Participants Who Experienced Adverse Events (AEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol TherapyTime frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
- Phase 1: Percentage of Participants Who Experienced Serious Adverse Events (SAEs) From the First Dose of Protocol Therapy Through 30 Days After Administration of the Last Dose of Protocol TherapyTime frame: From first dose in Cycle 1 Day 1 until 30 days after the last dose of study drug in Cycle 6 Day 15 (up to Cycle 7 Day 15) (Cycle length=28 days)
- Phase 2: Percentage of Participants Who Achieved a Complete Remission (CR) Per Independent Review Facility (IRF) Assessment Per International Working Group (IWG) Criteria at End of Treatment (EOT) VisitTime frame: At end of treatment (EOT) visit 30 days after the last dose of study drug (at Month 7)
- Phase 2: Percentage of Participants Whose Disease Was Positron Emission Tomography (PET) Negative After 2 Cycles of Protocol Therapy Per IRF AssessmentTime frame: From first dose of study drug up to Cycle 2 Day 25 (Each Cycle length=28 days)
- Phase 2: Percentage of Participants Who Achieved a Partial Remission (PR) Per IRF Assessment Per IWG Criteria at EOT VisitTime frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
- Phase 2: Percentage of Participants Who Achieved an Overall Response Rate (ORR) Per IRF Assessment Per IWG Criteria at EOT VisitTime frame: At EOT visit 30 days after the last dose of study drug (at Month 7)
- Phase 2: Percentage of Participants Who Were Able to Complete 6 Cycles of Protocol Therapy at the Recommended DoseTime frame: From first dose of study drug up to Cycle 6 (Each Cycle length=28 days)
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Jardim das Americas
Paranã, Brazil
INCA - Instituto Nacional de Cancer
Rio de Janeiro, Brazil
GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer
São Paulo, Brazil
ICr - Instituto da Crianca - HCFMUSP
São Paulo, Brazil
Hospital Santa Marcelina
São Paulo, Brazil
Hospital Sao Rafael S/A
Salvador, Estado de Bahia, Brazil
Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
Florence, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia
Roma, Italy
Azienda Ospedaliera Citta della Salute e della Scienza di Torino
Torino, Italy
NHO Nagoya Medical Center
Nagoya, Aichi-ken, Japan
St. Marianna University School of Medicine Hospital
Kawasaki-shi, Kanagawa, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.